Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugsBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39318.419410.DB (Published 30 August 2007) Cite this as: BMJ 2007;335:416
- Andrew Cole
Patients' groups have welcomed the decision by the National Institute for Health and Clinical Excellence (NICE) to give the go ahead to two new drugs for arthritis and one for multiple sclerosis.
NICE has approved for use in the NHS in England and Wales rituximab (MabThera) for severe active rheumatoid arthritis and adalimumab (Humira) for active and progressive psoriatic arthritis. It also recommended natalizumab (Tysabri) to treat rapidly evolving, severe relapsing-remitting multiple sclerosis.
Rituximab in combination with methotrexate will be available to NHS patients who have failed to respond to other antirheumatoid drugs, including at least one tumour necrosis …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial